190 related articles for article (PubMed ID: 23781941)
1. Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.
Honton B; Despas F; Dumonteil N; Rouvellat C; Roussel M; Carrie D; Galinier M; Montastruc JL; Pathak A
Fundam Clin Pharmacol; 2014 Jun; 28(3):349-52. PubMed ID: 23781941
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
[TBL] [Abstract][Full Text] [Related]
3. [Bortezomib-associated acute congestive heart failure in a patient with multiple myeloma].
Aota Y; Gotoh A; Hanyu N; Honma T; Morisaki M; Yokoyama T; Kitagawa N; Komatsu N
Rinsho Ketsueki; 2015 Jan; 56(1):44-7. PubMed ID: 25745969
[TBL] [Abstract][Full Text] [Related]
4. Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature.
Bockorny M; Chakravarty S; Schulman P; Bockorny B; Bona R
Acta Haematol; 2012; 128(4):244-7. PubMed ID: 22964848
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib-induced skin eruption.
Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib: new drug. A last resort in myeloma: modest efficacy, major risks.
Prescrire Int; 2005 Jun; 14(77):94-8. PubMed ID: 15981389
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-induced acute congestive heart failure: a case report and review of literature.
Subedi A; Sharma LR; Shah BK
Ann Hematol; 2014 Oct; 93(10):1797-9. PubMed ID: 24599584
[No Abstract] [Full Text] [Related]
9. Acute pancreatitis caused by bortezomib.
Solakoglu T; Akyol P; Guney T; Dilek I; Atalay R; Koseoglu H; Akin E; Demirezer Bolat A; Buyukasik NS; Ersoy O
Pancreatology; 2013; 13(2):189-90. PubMed ID: 23561979
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
Prescrire Int; 2006 Jun; 15(83):98-100. PubMed ID: 16764098
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib and bilateral herpes zoster.
di Meo N; Bergamo S; Dondas A; Trevisan G
Acta Dermatovenerol Alp Pannonica Adriat; 2012; 21(1):21-2. PubMed ID: 22584902
[TBL] [Abstract][Full Text] [Related]
12. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Richardson P
Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
[No Abstract] [Full Text] [Related]
13. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T
Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib-associated fatal liver failure in a haemodialysis patient with multiple myeloma.
Cornelis T; Beckers EA; Driessen AL; van der Sande FM; Koek GH
Clin Toxicol (Phila); 2012 Jun; 50(5):444-5. PubMed ID: 22462599
[TBL] [Abstract][Full Text] [Related]
15. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
16. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
Tobinai K
Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
[No Abstract] [Full Text] [Related]
17. [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].
Titos-Arcos JC; León-Villar J; de Arriba de la Fuente F; Moreno Belmonte MJ; Iranzo Fernández MD
Farm Hosp; 2012; 36(4):275-81. PubMed ID: 22115856
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma.
Gupta A; Pandey A; Sethi S
Cardiovasc Toxicol; 2012 Jun; 12(2):184-7. PubMed ID: 21952908
[TBL] [Abstract][Full Text] [Related]
19. Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib.
Qayum A; Aleem A; Al Diab AR; Niaz F; Al Momen AK
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):63-8. PubMed ID: 20061695
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of bortezomib in relapsed multiple myeloma.
Jagannath S
Clin Adv Hematol Oncol; 2006 May; 4(5):2-3; discussion 8; suppl 13. PubMed ID: 16830423
[No Abstract] [Full Text] [Related]
[Next] [New Search]
